华特达因：达因药业两条生产线已通过澳大利亚TGA认证

Core Viewpoint - The company has made progress in its overseas business, particularly in product quality standards, but currently lacks significant revenue from international operations [1] Group 1: Product Quality and Certification - The company's production quality system aligns with international standards [1] - Two production lines have received TGA certification from Australia, achieving the highest A1 rating [1] Group 2: Current Business Focus - The company primarily addresses domestic children's clinical and nutritional health needs [1] - It is currently introducing high-quality overseas products or raw materials into the domestic market for cross-border business [1] - There is essentially no revenue generated from overseas business activities at this time [1]